Cirrhosis liver

Reading File

Finding Sources

Searching PubMed

"liver cirrhosis"[MeSH Terms] AND management

Reading File

Loading Image

I now have rich, comprehensive content from authoritative textbooks. Let me compile the full detailed answer.

Liver Cirrhosis

Definition

Cirrhosis is the diffuse transformation of the liver into regenerative parenchymal nodules surrounded by fibrous bands. It represents the end stage of any chronic liver disease and is the morphologic change most often associated with chronic liver disease. Importantly, not all chronic liver disease ends in cirrhosis, and not all cirrhosis leads to end-stage liver failure.

Robbins & Kumar Basic Pathology, p. 598

Normal vs. Cirrhotic Liver

(A) Normal liver - smooth surface, homogeneous texture. (B) Normal hepatic sinusoids with organized architecture. (C) Cirrhotic liver - orange-tawny color, irregular nodular surface. (D) Microscopic cirrhosis - disorganized architecture with regenerative nodules surrounded by fibrous bands (Masson trichrome stain).

Etiology / Causes

Major Causes

Cause	Notes
Alcoholic liver disease	Leading cause in Western countries
Non-alcoholic fatty liver disease (NAFLD/MASLD)	Increasingly prevalent globally
Chronic hepatitis B	Major cause worldwide
Chronic hepatitis C	Previously major; now largely treatable

Other Causes (each ≤2% of cases)

Cholestatic/autoimmune: Primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis
Biliary obstruction: Mechanical obstruction, biliary atresia, cystic fibrosis
Metabolic: Hemochromatosis, Wilson disease, α1-antitrypsin deficiency, glycogen storage diseases, porphyria
Vascular: Budd-Chiari syndrome, veno-occlusive disease, right-sided heart failure
Cryptogenic cirrhosis: No identifiable cause
Goldman-Cecil Medicine, Table 139-1

Pathogenesis

Key Cellular Mechanism - Hepatic Stellate Cell Activation

Hepatic stellate cells (Ito cells / perisinusoidal cells) reside in the space of Disse between hepatocytes and sinusoidal endothelial cells
Normally quiescent - serve as the main vitamin A storage site
In response to liver injury, they become activated:
- Lose vitamin A stores
- Proliferate
- Develop prominent rough ER
- Secrete extracellular matrix (collagen types I and III, sulfated proteoglycans, glycoproteins)
- Transform into contractile myofibroblasts

Sinusoidal Capillarization

Normal hepatic sinusoids lack a basement membrane and contain large fenestrae (100-200 nm), allowing passage of large molecules up to 250,000 daltons
Collagen deposition in the space of Disse causes defenestration ("capillarization" of sinusoids)
Alters plasma-hepatocyte exchange and reduces sinusoidal diameter (worsened by stellate cell contraction)
Goldman-Cecil Medicine, p. 1615

Morphology

Gross: The entire liver is transformed into regenerative parenchymal nodules separated by fibrous bands. The liver surface is nodular and irregular.

Microscopic: Nodular parenchyma surrounded by fibrous septa. The pattern of scarring (portal-portal vs. portal-central linking), degree of parenchymal loss, and extent of vascular thrombosis vary by etiology.

Ductular reactions: Stem cell activation gives rise to ductlike structures that increase with disease progression and are most prominent in cirrhosis.

Reversibility: Fibrosis and even established cirrhosis may partially regress after disease remission or cure. Scars become thinner, fragment, and adjacent nodules coalesce into larger islands.

Staging: Compensated vs. Decompensated

Cirrhosis is classified into two main prognostic stages:

Stage	Definition	Prognosis
Compensated	No ascites, variceal hemorrhage, encephalopathy, or jaundice	Median survival >12 years
Decompensated	Development of any of the above	Median survival ~2 years

Ascites is the most common first sign of decompensation (present in 80% of decompensated patients).

Scoring Systems

Child-Turcotte-Pugh (CTP) Score (Range 5-15)

Parameter	1 point	2 points	3 points
Ascites	None	Grade 1-2 (easy to treat)	Grade 3-4 (refractory)
Hepatic encephalopathy	None	Grade 1-2	Grade 3-4 (spontaneous)
Bilirubin (mg/dL)	<2	2-3	>3
Albumin (g/dL)	>3.5	2.8-3.5	<2.8
PT (sec > control)/INR	<4 / <1.7	4-6 / 1.7-2.3	>6 / >2.3

Child A: Score 5-6 (well-compensated)
Child B: Score 7-9
Child C: Score 10-15 (severe decompensation)

MELD Score

Uses serum bilirubin, INR, and creatinine. Primary tool for liver transplant prioritization.

Complications (Pathophysiology)

The two main pathophysiologic consequences are portal hypertension and liver insufficiency.

1. Portal Hypertension

Caused by:

Fixed component: Fibrosis + regenerative nodule compression of sinusoids
Functional component: Active vasoconstriction from intrahepatic nitric oxide deficiency + enhanced vasoconstrictors

Results in:

Portosystemic shunts - most importantly, esophagogastric varices (develop in ~40% of advanced disease) - risk of massive fatal hematemesis
Splenomegaly - can cause hypersplenism (thrombocytopenia, pancytopenia)
Ascites - transudate (<3 g/dL protein); serum-ascites albumin gradient ≥1.1 g/dL; ~85% of all ascites cases are due to cirrhotic portal hypertension

2. Liver Insufficiency

Jaundice - impaired bilirubin excretion
Coagulopathy - reduced clotting factor synthesis
Hypoalbuminemia - reduced plasma proteins → contributes to ascites and edema
Hyperestrogenemia (in males) - impaired estrogen catabolism → palmar erythema, spider angiomas, gynecomastia, hypogonadism
Hepatic encephalopathy - result of both portal shunting and liver insufficiency

3. Ascites Complications

Spontaneous bacterial peritonitis (SBP)
Hepatorenal syndrome (HRS) - functional renal failure

4. Renal Consequences (Guyton physiology)

Reduced plasma protein → reduced colloid osmotic pressure → fluid leakage into peritoneum
Portal hypertension impedes portal blood flow → raises capillary pressure in portal vascular bed
Kidney retains salt and water (RAAS activation) in attempt to restore plasma volume
Vascular capacity may actually increase (portal vein distension), worsening the cycle

5. Hepatocellular Carcinoma (HCC)

Most chronic liver diseases with cirrhosis predispose to HCC development.

Clinical Features

About 40% of individuals with cirrhosis are asymptomatic until advanced disease.

Symptoms

Anorexia, weight loss, weakness (nonspecific)
Pruritus - severe jaundice causes bile salt accumulation; may be severe enough to cause skin excoriation
Abdominal distension (ascites)

Signs

System	Finding
Skin	Jaundice, palmar erythema, spider angiomas, excoriations
Endocrine (males)	Gynecomastia, testicular atrophy, loss of body hair
Abdomen	Hepatomegaly (early), shrunken liver (late), splenomegaly, ascites, caput medusae
Neurological	Asterixis (hepatic flap), confusion (encephalopathy)
Hematologic	Bruising, bleeding (coagulopathy)

Variceal Hemorrhage

Gastroesophageal varices in ~50% of newly diagnosed cirrhosis
Prevalence: 40% in Child A → 85% in Child C
Varices develop/grow at 7-8% per year
First bleed rate: ~5%/year (small varices), ~15%/year (medium/large varices)
Risk factors for bleeding: large varices, severe liver disease, red wale markings

Laboratory Findings

Test	Finding in Cirrhosis
Bilirubin	Elevated (conjugated + unconjugated)
ALT/AST	Elevated (may normalize in end-stage)
Albumin	Low
PT/INR	Prolonged
Platelets	Low (hypersplenism)
Sodium	May be low (dilutional hyponatremia, <130 mEq/L in ~25%)
Creatinine	Elevated if HRS develops

Management Overview

Treat the Underlying Cause

Alcohol cessation
Antiviral therapy for hepatitis B (tenofovir/entecavir) or hepatitis C (direct-acting antivirals - cure possible even with established cirrhosis)
Weight loss/metabolic control for NAFLD/MASLD

Compensated Cirrhosis

Surveillance for varices (endoscopy) and HCC (ultrasound every 6 months)
Non-selective beta-blockers (propranolol/carvedilol) for variceal prophylaxis if varices present

Decompensated Cirrhosis

Complication	Management
Ascites	Salt restriction + diuretics (spironolactone ± furosemide); large-volume paracentesis for tense ascites + IV albumin
SBP	IV cefotaxime/ceftriaxone; prophylaxis with norfloxacin
Variceal hemorrhage	IV terlipressin or octreotide + endoscopic band ligation; TIPS if refractory
Hepatic encephalopathy	Lactulose ± rifaximin; identify and treat precipitants
HRS	Terlipressin + IV albumin; TIPS; ultimately liver transplant
Hyponatremia	Fluid restriction; vaptans in select cases

Liver Transplantation

Definitive treatment for end-stage disease
MELD score used for waitlist prioritization
5-year survival post-transplant: ~75-80%

Prognosis

Compensated: Median survival >12 years; decompensation develops at 5-7% per year
Decompensated: Median survival ~2 years without transplant
Leading causes of death: liver failure, HCC, variceal hemorrhage, sepsis
Cirrhosis may partially regress if the underlying cause is eliminated (most dramatically seen after HCV cure or alcohol abstinence), though portal hypertension may persist due to irreversible shunts

Sources:

Robbins & Kumar Basic Pathology, pp. 598-600
Goldman-Cecil Medicine International Edition, pp. 1614-1620
Guyton and Hall Textbook of Medical Physiology, p. 390

Cirrhosis liver

I just covered liver cirrhosis in detail in my previous response above. Here's a quick summary of what was covered:

Definition: Diffuse transformation of the liver into regenerative parenchymal nodules surrounded by fibrous bands - the end stage of chronic liver disease.

Key Topics Covered:

Etiology (alcohol, NAFLD, hepatitis B/C, metabolic diseases)
Pathogenesis (hepatic stellate cell activation, sinusoidal capillarization)
Morphology with gross and microscopic images
Compensated vs. decompensated staging
Child-Turcotte-Pugh and MELD scoring
Complications (portal hypertension, ascites, varices, encephalopathy, HRS, SBP, HCC)
Clinical features and lab findings
Management of each complication
Prognosis

Is there a specific aspect of cirrhosis you'd like me to go deeper on? For example:

Pathology - detailed histology, fibrosis grading
Complications - management of ascites, varices, or hepatic encephalopathy in detail
Scoring/prognosis - MELD score calculation, transplant criteria
Specific etiology - alcoholic vs. viral vs. NAFLD cirrhosis
Pharmacology - drugs used in management

Just let me know what you need!

This is a shared conversation. Sign in to Orris to start your own chat.